Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Patent
1998-04-28
2000-09-12
Reamer, James H.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
A01N 3302
Patent
active
061179124
ABSTRACT:
The present invention is directed to improved methods for treating certain selegiline-responsive diseases or conditions and, more specifically, to methods in which selegiline is administered buccally or sublingually. Selegiline may be used ether as a free base or as a pharmaceutically acceptable acid addition salt. The selegiline-responsive diseases or conditions include neuronal-degenerative diseases and conditions, such as Alzheimer's disease and neuronal damage from hypoxia, stroke, ischemia, and trauma, and dopaminergic-related, selegiline responsive diseases and conditions such as depression and ADHD.
REFERENCES:
patent: 4812481 (1989-03-01), Reischig et al.
patent: 4826875 (1989-05-01), Chiesi
patent: 4861800 (1989-08-01), Buyske
patent: 5057321 (1991-10-01), Edgren et al.
patent: 5151419 (1992-09-01), Perenyi et al.
patent: 5151449 (1992-09-01), Milgram
patent: 5192550 (1993-03-01), Edgren et al.
patent: 5192808 (1993-03-01), Ruehl et al.
patent: 5221536 (1993-06-01), Edgren et al.
patent: 5242950 (1993-09-01), Fries Hastings
patent: 5266332 (1993-11-01), Dong et al.
patent: 5276057 (1994-01-01), Milgram et al.
patent: 5304379 (1994-04-01), Cormier et al.
patent: 5332576 (1994-07-01), Mantelle
patent: 5354885 (1994-10-01), Milman et al.
patent: 5387615 (1995-02-01), Milgram et al.
patent: 5444095 (1995-08-01), Tatton et al.
patent: 5446070 (1995-08-01), Mantelle
patent: 5607691 (1997-03-01), Hale et al.
Buys, et al., "(-)-Deprenyl Increases the Survival of Rat Retinal Ganglion Cells After Optic Nerve Crush," Current Eye Res. 14 :119-126 (1995).
Chrisp, et al., "Selegiline, A Review of Its Pharmacology, Symptomatic Benefits and Protective Potential in Parkinson's Disease," Drugs & Aging 1 :228-248 (1991).
Feigin, et al., "A Double-Blind, Placebo-Controlled, Cross-Over Study of Deprenyl in Children With Tourette's Syndrome (TS) and Attention-Deficit Hyperactivity Disorder (ADHD)," Neurology 45:A254-A255 (1995).
Green, "The Treatment of Attention-Deficit Hyperactivity Disorder With Nonstimulant Medications," Pediatric Psychopharmacol. 4:169-195 (1995).
Jankovic, "Deprenyl in Attention Deficit Associated With Tourette's Syndrome," Arch. Neurol. 50:286-288 (1993).
Rapoport, et al., "New Drug Trials in Attention Deficit Disorder," Psychopharmacol. Bull. 21:232-236 (1985).
Trope, et al., "(-) Deprenyl Improves Visual Function in Glaucoma Patients," Invest. Ophthalmol. & Vis. Science 35 :2178 (1994).
Zametkin, et al., "Noradrenergic Hypothesis of Attention Deficit Disorder With Hyperactivity: A Critical View," Psychopharmacology: The Third Generation of Progress, Herbert Y. Meltzer, Editor, Raven Press, New York, 837-842 (1987).
Heinonen et al, Clinical Pharmacology & Therapeutics, vol. 56, No. 6, pp. 742-49, 1994.
Reamer James H.
Sanzo Michael A.
Somerset Pharmaceuticals, Inc.
LandOfFree
Sublingual and buccal administration of selegiline for treating does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sublingual and buccal administration of selegiline for treating , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sublingual and buccal administration of selegiline for treating will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-96778